Empower Capital

Empower Capital is a EUR 21 million fund established to provide equity and quasi-equity funding to growing Bulgarian companies. Financed by the European Investment Fund - JEREMIE Initiative Bulgaria, the team offers extensive international operating experience, expertise, and industrial knowledge to support SMEs. With a successful track record in investing and managing companies in Bulgaria, they specialize in raising funds from various investors and facilitating exits to international buyers. Empower Capital plays a crucial role in helping companies reach their potential by identifying valuable organizations and providing growth capital, strategic guidance, and operational support to strong management teams.

Tihomir Dyankov

Investment Manager

Stanislav Nikolaev

Partner, COO

Slavcho Parushev

Partner, Head of Portfolio Operations

1 past transactions

Fidelis Research

Venture Round in 2017
Fidelis Research is a specialized provider of human tissue procurement and clinical trial services, catering to researchers, contract research organizations, and pharmaceutical companies. Founded by professionals with extensive experience in the medical research field, the company focuses on delivering integrated services throughout the entire product development cycle, from pre-clinical stages to market authorization. Fidelis Research offers a range of services, including biospecimen collection, laboratory processing and analysis, and support for clinical research and patient programs. By engaging in various human tissue procurement projects and clinical trials, the company has established strong relationships with key opinion leaders across its operational regions. Fidelis Research is recognized for its commitment to quality and flexibility, making it a trusted partner for clients seeking both commonly used and rare human tissue and biofluid specimens for translational research.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.